Best Warren Buffett Companies To Own For 2014

Someone who reads my articles asked me this question: I've read a few of your articles, especially on those about Warren Buffett�� investment style�� would be grateful for your help in clarifying a question about Warren Buffett�� purchase of Coca-Cola (KO).

Throughout 1988 and 1998 Warren Buffett acquired more than $1 billion of KO stock. At the time Wall Street deduced Buffett paid way too much for the earnings indicating a high P/E.

Some investors believe Warren Buffett used some sort of discounted cash flow analysis to value his purchase in 1988 and 1989, which he projected out ten years. However from what I understand you may not be convinced that Warren Buffett uses discounted cash flow analysis in his valuation of businesses. I would be very interested to know how you think Warren Buffett valued his purchase.

Kind Regards,
Caesar

As best I can, I��l let Warren Buffett answer the question himself. Let�� start with what Warren Buffett said back in the 1990s at Notre Dame:

Top 5 Diversified Bank Companies To Invest In Right Now: Jack Henry & Associates Inc.(JKHY)

Jack Henry & Associates, Inc. (JHA) provides integrated computer systems and services for in-house and outsourced data processing to commercial banks, credit unions, and other financial institutions primarily in the United States. It engages in processing transactions, automating business processes, and managing information services. The company?s Jack Henry Banking brand provides integrated data processing systems to de novo or start-up institutions and mid-tier banks, as well as markets three core banking software systems, such as SilverLake, a robust IBM i-based system designed for commercial-focused banks; CIF 20/20, a parameter-driven and easy-to-use system; and Core Director, a Windows-based and client/server system that offers intuitive point-and-click operation. Its Symitar brand supports credit unions with information and transaction processing platforms that provide enterprise-wide automation. This brand?s solutions include Episys, a robust IBM p-based system p rimarily designed for credit unions; and Cruise, a Windows-based and client/server system for credit unions. The company?s ProfitStars brand provides specialized products and services that enhance the performance of financial service organizations and corporate entities. Its iPay Technologies brand operates as an electronic bill pay for banks and credit unions with turnkey, and configurable retail and small business electronic payment platforms. JHA also offers complementary solutions comprising business intelligence and bank management, retail and business banking, member and member business services, Internet banking and electronic funds transfer, risk management and protection, and item and document imaging solutions. In addition, it provides data conversion, software implementation, training, and support services, as well as sells hardware systems. The company has strategic relationship with IBM Corporation. JHA was founded in 1969 and is based in Monett, Missouri.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Jack Henry & Associates (Nasdaq: JKHY  ) , whose recent revenue and earnings are plotted below.

• [By Jay Jenkins]

  For U.S. Bancorp, a fine of this magnitude is nothing more than a slap on the wrist. However, it is a harbinger for change in how regulators view third-party relationships. Banks will now have to think long and hard about outsourcing, even to reputable companies like Jack Henry and Associates (NASDAQ: JKHY  ) and Fiserv (NASDAQ: FISV  ) .�

• [By Seth Jayson]

  Margins matter. The more Jack Henry & Associates (Nasdaq: JKHY  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Jack Henry & Associates's competitive position could be.

• [By Jay Jenkins]

  It doesn't matter if the bank is a mega bank like Bank of America (NYSE: BAC  ) , a regional player like BB&T (NYSE: BBT  ) , or a third-party software provider like Jack Henry and Associates (NASDAQ: JKHY  ) , the capabilities and usability of online banking services are noticeably stuck in the mud.�

Best Warren Buffett Companies To Own For 2014: Apollo Investment Corporation(AINV)

Apollo Investment Corporation is business development company and operates as a closed-end management investment company. The company invests in middle market companies. It provides direct equity capital, mezzanine and senior secured loans, and subordinated debt and loans. It also seeks to invest in PIPES transactions. The company may also invest in public companies that are thinly traded and may acquire investments in the secondary market. It prefers to invest in warrants, makes equity co-investments, and may also invest in cash equivalents, U.S. government securities, high-quality debt investments that mature in one year or less, high-yield bonds, distressed debt, non-U.S. investments, or securities of public companies that are not thinly traded. The company typically invests in building materials, business services, cable television, chemicals, consumer products, direct marketing, distribution, energy and utilities, financial services, healthcare, manufacturing, media, publishing, retail and transportation. It primarily invests between $20 million and $250 million in its portfolio companies. The company seeks to make investments with stated maturities of five to ten years.

Advisors' Opinion:

• [By MONEYMORNING]

  He's much better off in "total return" holdings, like Apollo Investment Corp. (Nasdaq: AINV) which we covered right here, and Kinder Morgan Energy Partners LP (NYSE: KMP), another long-term winner.

• [By Rich Bieglmeier]

  Expensive or not, dividend investors might be interested in this week's highlighted insider buying candidate: Apollo Investment Corporation (AINV).

• [By Tim Melvin]

  Here are a couple private equity-powered dividend stocks on my radar right now:

  Apollo Investment (AINV)

  Apollo Global Management (APO) is one of the world�� largest asset management and private equity firms with more than $100 billion under management. Its largest publicly offered vehicle is Apollo Investment (AINV), a business development company that invests in and ends to middle-market companies and pays out 90% of its net income to shareholders.

• [By James Brumley]

  The seller will let up as soon as the news is a fading memory, which should be soon.

  Apollo Investment Corp. (AINV)

  AINV Dividend Yield: 9.7%

Best Warren Buffett Companies To Own For 2014: Pioneer Natural Resources Co (PXD)

Pioneer Natural Resources Company (Pioneer),incorporated on April 4, 1997, is an independent oil and gas exploration and production company with operations in the United States and South Africa. Pioneer is a holding company whose assets consist of direct and indirect ownership interests in, and whose business is conducted substantially through, its subsidiaries. The Company sells homogenous oil, natural gas liquid (NGL) and gas units. The Company provides administrative, financial, legal and management support to United States and South Africa subsidiaries that explore for, develop and produce proved reserves. The Company�� continuing operations are principally located in the United States in the states of Texas, Kansas, Colorado and Alaska. During February 2011, the Company completed the sale of Pioneer Natural Resources Tunisia Ltd. and Pioneer Natural Resources Anaguid Ltd. In April 2012, it acquired Carmeuse Industrial Sands (CIS). In August 2012, the Company sold its South Africa business to The Petroleum Oil and Gas Corporation of South Africa (SOC) Ltd. (PetroSA). Effective December 17, 2013, Pioneer Natural Resources Company and Pioneer Southwest Energy Partners L.P announced the completion of the merger of Pioneer Southwest Energy Partners L.P with a wholly owned subsidiary of Pioneer Natural Resources Company, with Pioneer Southwest Energy Partners L.P surviving the merger as an indirect wholly owned subsidiary of Pioneer Natural Resources Company.

The Company has 15 owned drilling rigs operating in the Spraberry field, and as of December 31, 2011, had Company-owned fracture stimulation fleets totaling 250,000 horsepower supporting drilling operations in the Spraberry, Eagle Ford Shale and Barnett Shale Combo areas. The Company also owns other field service equipment, including pulling units, fracture stimulation tanks, water transport trucks, hot oilers, blowout preventers, construction equipment and fishing tools. The Company owns a 52.4% limited partner interest and a 0.1% ! general partner interest in Pioneer Southwest Energy Partners L.P. and its subsidiaries (Pioneer Southwest). The Company�� proved reserves totaled 1,063 million barrel of oil equivalent at December 31, 2011. Approximately 83% of the Company�� proved reserves at December 31, 2011 are located in the Spraberry field in the Permian Basin area, the Hugoton and West Panhandle fields in the Mid-Continent area and the Raton field in the Rocky Mountains area.

Permian Basin

The Spraberry field encompasses eight counties in West Texas. The field is approximately 150 miles long and 75 miles wide at its widest point. The oil produced is West Texas Intermediate Sweet, and the gas produced is casinghead gas with an average energy content of 1,400 British thermal unit. The oil and gas are produced primarily from four formations, the upper and lower Spraberry, the Dean and the Wolfcamp, at depths ranging from 6,700 feet to 11,300 feet. During the year ended December 31, 2011, the Company drilled 706 wells in the Spraberry field and its total acreage position approximated 820,000 gross acres (691,000 net acres). The Company has 44 rigs operating, of which 41 are drilling vertical wells and three are drilling horizontal wells. The Company completed its second horizontal well in the Upper/Middle Wolfcamp Shale in Upton County, Texas with a 30-stage fracture stimulation in a 5,800-foot lateral section. The Company is focusing its horizontal efforts on more than 200,000 acres in the southern part of the field to hold acreage. The Company continues to test down spacing in the Spraberry field from 40 acres to 20 acres. Sixteen 20-acre wells were drilled in 2011, with 10 of these wells having been placed on production. These 20-acre wells were drilled to the Lower Wolfcamp interval, with a few deepened to the Strawn interval.

Mid-Continent

The Hugoton field in southwest Kansas is a producing gas fields in the continental United States. The gas is produced from the Chase an! d Council! Grove formations at depths ranging from 2,700 feet to 3,000 feet. The Company�� Hugoton properties are located on approximately 284,000 gross acres (245,000 net acres), covering approximately 400 square miles. The Company has working interests in approximately 1,220 wells in the Hugoton field, approximately 1,000 of which it operates. The Company operates substantially all of the gathering and processing facilities, including the Satanta plant, which processes the production from the Hugoton field. In January 2011, the Company sold a 49% interest in the Satanta plant to an unaffiliated third party for the third party�� commitment to dedicate gas volumes to the Satanta plant. The Company is also exploring opportunities to process other gas production in the Hugoton area at the Satanta plant. By maintaining operatorship of the gathering and processing facilities, the Company is able to control the production, gathering, processing and sale of its Hugoton field gas and NGL production.

The West Panhandle properties are located in the panhandle region of Texas. These reserves are attributable to the Red Cave, Brown Dolomite, Granite Wash and fractured Granite formations at depths no greater than 3,500 feet. The Company�� gas has an average energy content of 1,365 British thermal unit and is produced from approximately 680 wells on more than 259,000 gross acres (252,000 net acres) covering over 375 square miles. The Company controls 100% of the wells, production equipment, gathering system and the Fain gas processing plant for the field.

Raton

The Raton Basin properties are located in the southeast portion of Colorado. The Company owns approximately 227,000 gross acres (201,000 net acres) in the center of the Raton Basin and produces CBM gas from the coal seams in the Vermejo and Raton formations from approximately 2,300 wells. The Company owns the majority of the well servicing and fracture stimulation equipment that it utilizes in the Raton field, allowing it to! control ! costs and insure availability.

South Texas Eagle Ford Shale and Edwards

The Company�� drilling activities in the South Texas area during 2011 were primarily focused on delineation and development of Pioneer�� substantial acreage position in the Eagle Ford Shale play. The Company drilled 94 horizontal Eagle Ford Shale wells during 2011, with average lateral lengths of approximately 5,500 feet and 13-stage fracture stimulations. EFS Midstream LLC (EFS Midstream) is obligated to construct midstream assets in the Eagle Ford Shale area. Eight of the 12 planned central gathering plants (CGPs) were completed as of December 31, 2011.

Barnett Shale

During 2011, the Company continued to increase its acreage position in the liquid-rich Barnett Shale Combo area in North Texas. In total, the Company has accumulated approximately 92,000 gross acres in the liquid-rich area of the field and has acquired approximately 340 square miles of three dimensional (3-D) seismic covering its acreage. The Company�� total lease holdings in the Barnett Shale play now approximate 142,000 gross acres (108,000 net acres). During 2011, the Company had two drilling rigs operating and drilled 44 Barnett Shale Combo wells. The Company also commenced operating a Company-owned fracture stimulation fleet in the area during the second quarter of 2011.

Alaska

The Company owns a 70% working interest and is the operator of the Oooguruk development project. The Company has drilled 12 production wells and eight injection wells of the estimated 17 production and 16 injection wells planned to develop this project.

International

During 2011, the Company�� international operations were located in Tunisia and offshore South Africa. During February 2011, the Company completed the sale of the Company�� share holdings in Pioneer Tunisia to an unaffiliated third party.

Advisors' Opinion:

• [By Brian Stoffel]

  2. Pioneer Natural Resources (NYSE: PXD  ) , P/E of 237
  Pioneer is an independent oil and natural gas company that's focusing on North America's various shale plays. It's important to understand two key variables that play an enormous role in whether Pioneer is worth your money.

• [By Lee Jackson]

  Pioneer Natural Resources Co. (NYSE: PXD) is a huge player in the Permian basin in Texas, and it has been a huge winner for shareholders this year. Rumors have swirled the last half of this year that one of the big integrateds may target Pioneer as a takeover candidate. It would be a very expensive deal, as the company’s market cap is almost 25 billion. The Merrill Lynch price target for the stock is a gigantic $275. The consensus number is lower at $233.75, and shares�closed Monday at $185.19.

• [By Arjun Sreekumar]

  Similarly, in the Permian Basin of West Texas, where Apache is currently the second-largest producer, it has managed to sharply boost estimated ultimate recoveries by drilling deeper laterals and employing a greater number of frac stages. Other companies, such as Pioneer Natural Resources (NYSE: PXD  ) and LINN Energy (NASDAQ: LINE  ) , have seen similar success in the Permian by employing secondary oil recovery techniques.

Best Warren Buffett Companies To Own For 2014: Wetherspoon(jd)

JD Wetherspoon plc owns and operates pubs. The company operates 823 pubs that offer food and drinks in England, northern Ireland, Scotland, and Wales. It also operates hotels. The company was founded in 1979 and is headquartered in Watford, the United Kingdom.

Advisors' Opinion:

• [By Lisa Levin]

  JD.com (NASDAQ: JD) shares declined 4.03% to $28.80 in pre-market trading after the company reported a quarterly net loss of 582.5 million yuan ($93.9 million).

• [By Lisa Levin]

  JD.com (NASDAQ: JD) dropped 3.35% to $29.00 after the company reported a quarterly net loss of 582.5 million yuan ($93.9 million).

  Intercept Pharmaceuticals (NASDAQ: ICPT) shares fell 2.60% to $288.66 after falling 3.66% on Thursday.

• [By Gillian Tan]

  The hiring caps a busy week for Bank of America, which co-led the IPO of�Chinese online retailer JD.com(JD). The stock jumped as much as 20% higher on its debut�Thursday.

Best Warren Buffett Companies To Own For 2014: Medtronic Inc (MDT)

Medtronic, Inc. (Medtronic), incorporated on April 23, 1957, is engaged in medical technology - alleviating pain, restoring health, and extending life for millions of people worldwide. As of April, 27, 2012, the Company functions in two operating segments that manufacture and sells device-based medical therapies. The Company's operating segments include Cardiac and Vascular Group, which consists of Cardiac Rhythm Disease Management (CRDM) and CardioVascular, and Restorative Therapies Group, which consists of Spinal, Neuromodulation, Diabetes and Surgical Technologies. Medtronic serves hospitals, physicians, clinicians, and patients in more than 120 countries worldwide. The Company's primary customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. In August 2013, Medtronic, Inc. announced the closing of the acquisition of Cardiocom. Effective September 3, 2013, Medtronic Inc acquired a 30% stake in NGC Medical SpA.

Cardiac Rhythm Disease Management

CRDM develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), and information systems for the management of patients with CRDM devices. The Company's principal products offered by CRDM business include Implantable Cardiac Pacemakers (Pacemakers), Implantable Cardioverter Defibrillators (ICDs), Implantable Cardiac Resynchronization Therapy Devices (CRT-Ds and CRT-Ps), AF Products, Diagnostics and Monitoring Devices and Patient Management Tools. The Company's pacemaker systems are compatible with certain magnetic resonance imaging (MRI) machines. This includes the Revo MRI SureScan with United States Food and Drug Administration approval and the Advisa and Ensura MRI SureScan models with Conformite Europeene (CE)! Mark approval. Medtronic also continues to market the Adapta product family, which includes the Adapta, Versa, Sensia, and Relia models.

The Medtronic ICDs is the Protecta family with SmartShock technology, including the Lead Integrity Alert, a technology designed to improve the detection of lead fractures. Devices in the ICD family are the Protecta XT, Protecta, Cardia, and Egida models. Medtronic also continues to market the Secura and Maximo II devices. The Medtronic CRT-Ds is the Protecta family with SmartShock technology, including Protecta XT and Protecta, and the CRT-P devices are Consulta and Syncra. Medtronic also continues to market the Consulta, Cardia, Egida, and Maximo II CRT-D devices. In addition to these devices, Medtronic has an offering of left heart leads and delivery catheters with its Attain family of products. The Company's portfolio of AF products includes the Arctic Front Cardiac CryoAblation Catheter designed to treat paroxysmal AF by performing pulmonary vein isolation. The Company also offers the Reveal XT Insertable Cardiac Monitor, which is designed to identify and quantify episodes of AF. The Reveal DX and Reveal XT Insertable Cardiac Monitors devices are used to record the heart's electrical activity before, during, and after transient symptoms such as syncope and palpitations to help provide a diagnosis. It has a number of patient management tools, such as CareLink, Paceart, and CardioSight Service. CareLink enables patients to transmit data from their pacemaker, ICD, CRT-D, or Insertable Cardiac Monitors using a portable monitor that is connected to a standard telephone line or cellular network using the Medtronic M-Link accessory.

The Company competes with St. Jude Medical, Inc., Boston Scientific Corporation, Biotronik, Inc. and Sorin Group.

CardioVascular

CardioVascular is comprised of three businesses: Coronary, Endovascular and Peripheral, and Structural Heart. The Coronary business includes therapies to treat ! coronary ! artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, along with a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories. The products offered by its Coronary business include Percutaneous Coronary Intervention (PCI) and Renal Denervation. The Endovascular and Peripheral business is comprised of a range of products and therapies to treat abdominal and thoracic aortic aneurysms and peripheral vascular disease (PVD). The Company's products include endovascular stent graft systems, embolic protection systems, and stent systems for the treatment of narrowed iliac arteries. The products offered by the Company's Endovascular and Peripheral business include Endovascular Stent Grafts and Peripheral Vascular Intervention (PVI). The Structural Heart business offers a range of products and therapies to treat a variety of heart valve disorders. The Company's products include products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascularization surgery, and surgical ablation products. The Company's principal products offered by its Structural Heart business include Heart Valves, Transcatheter Heart Valves, Arrested Heart Surgery, Beating Heart Surgery and Surgical Ablation.

The Company competes with Abbott Laboratories, Boston Scientific, and Johnson & Johnson, Cook, Inc., W. L. Gore & Associates, Inc., Endologix, Inc., C.R. Bard, Inc., Edwards LifeSciences Corporation, St. Jude, Terumo Medical Corporation and Sorin Group.

Spinal

The Company's Spinal business develops, manufactures, and markets a range of medical devices and implants used in the treatment of the spine and musculoskeletal system. The Company's products and therapies treat a range of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumours, fractures ! of the sp! ine, and stenosis. The Company's Spinal business also provides biologic solutions for the dental and orthopedic markets. The Company's Spinal products are used in spinal fusion of both the thoracolumbar region, referring to the mid to lower vertebrae, as well as of the cervical region, or upper spine and neck vertebrae. Products used to treat spinal conditions include rods, pedicle screws, hooks, plates, and interbody devices, as well as biologics products, primarily bone growth substitutes including bone graft extenders and structural allografts such as dowels and wedges. The products offered by the Company's Spinal business include Thoracolumbar Products, Cervical Products and Biologics Products.

The Company competes with DePuy Spine, Inc., Synthes, Inc., Stryker Corporation, NuVasive, Inc., Globus Medical, Inc., Zimmer, Inc., Alphatec Spine, Inc., Orthofix International N.V., Biomet, Inc. and Johnson & Johnson.

Neuromodulation

The Company's Neuromodulation business develops, manufactures, and markets medical devices for the treatment of chronic pain, movement disorders, psychological disorders, and urological, fecal, and gastroenterological disorders. The l products offered by the Company's Neuromodulation business includes Neurostimulators for Chronic Pain, Implantable Drug Delivery Systems, Deep Brain Stimulation (DBS) Systems and Urology, Fecal, & Gastroenterology Devices. The Company's portfolio of products includes the RestoreSensor (rechargeable), with the Company's AdaptiveStim technology, as well as the RestoreULTRA (rechargeable), RestoreADVANCED (rechargeable), and PrimeADVANCED (non-rechargeable) neurostimulation systems. The SynchroMed II Programmable Infusion System delivers small quantities of drug directly into the intrathecal space surrounding the spinal cord. These devices are used to treat chronic, intractable pain and severe spasticity associated with cerebral palsy, multiple sclerosis, spinal cord and traumatic brain injuries, and stroke.

DBS uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver carefully controlled electrical stimulation to precisely targeted areas in the brain. The Company's family of Activa Neurostimulators for DBS includes Activa SC (single-channel primary cell), Activa PC (dual channel primary cell), and Activa RC (dual channel rechargeable). The Company's therapeutic portfolio for urology and gastroenterology includes the InterStim Therapy System, which treats the symptoms of overactive bladder, urinary retention, and chronic fecal incontinence, and the Enterra Therapy System for the treatment of chronic nausea and vomiting caused by gastroparesis of diabetic or idiopathic origin for drug refractory patients.

The Company's competes with Boston Scientific, St. Jude., Urologix, Inc. and Allergan.

Diabetes

The Company's Diabetes business develops, manufactures, and markets advanced, integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring systems, and therapy management software. The products offered by the Company's Diabetes business includes Integrated Diabetes Management Solutions, Professional CGM and CareLink Therapy Management Software. Outside the United States, the Company offers its Paradigm Veo System, an integrated system that includes a Low Glucose Suspend feature that automatically suspends insulin delivery when glucose levels become too low. In the United States, the Company offers the Paradigm Revel System, which incorporates new CGM features, including predictive alerts that can give early warning to people with diabetes so they can take action to prevent dangerous high or low glucose events. Medtronic offers physicians a Professional CGM product called the iPro CGM and iPro2 Professional CGM. The Company offers Web-based therapy management software solutions, including CareLink Personal software for patients and CareLink Pro software, to helps patients and their health care prov! iders con! trol their diabetes.

The Company competes with DexCom, Inc., Insulet Corporation, Johnson & Johnson and Roche Ltd.

Surgical Technologies

The Company's Surgical Technologies business develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose, and throat (ENT) and certain neurological disorders. In addition, the business develops, manufactures, and markets image-guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus, and orthopedic surgeries. The products offered by the Company's Surgical Technologies business includes ENT, Neurological Technologies, Navigation and Advanced Energy. The ENT products treat diseases and conditions, such as NIM Nerve Monitoring Systems, Fusion ENT Navigation System, Hydrodebrider Endoscopic Sinus Irrigation System, Meniett Device for Meniere's Disease, Pillar Procedure for Snoring and Sleep Apnea, and Repose System for Obstructive Sleep Apnea. The Neurological Technologies products treat certain neurological disorders and conditions, such as Midas Rex Spine Shaver, the Midas Rex MR7 Pneumatic Platform, the Midas Rex Legend EHS High Speed Surgical Drill, the Strata Family of Adjustable Valves for the treatment of Hydrocephalus, Duet External Drainage & Monitoring System, the IPC System, and the Subdural Evacuating Port System.

The Navigation products are used in cranial, spinal, sinus, and orthopedic surgeries, such as the StealthStation S7 Navigation and i7 Integrated Navigation Systems, the O-Arm 2D/3D Surgical Imaging System, and the PoleStar Surgical MRI System. The products make up the Advanced Energy business: PEAK Surgery System, a tissue dissection system that consists of the PEAK PlasmaBlade and the PULSAR Generator and is cleared for use in a variety of settings, including ENT, plastic reconstructive and general surgery; and the Aquamantys System, which uses patented Transcollation technology to ! provide h! aemostatic sealing of soft tissue and bone and is cleared for use in a range of surgical procedures, including orthopedic surgery, spine, solid organ resection and thoracic procedures.

The Company competes with Gyrus ACMI, Stryker Corporation, Johnson & Johnson, Integra LifeSciences Holdings Corporation, BrainLAB, Inc., GE Healthcare, Siemens Medical Solutions USA, Inc., Philips Medical Systems, Covidien and ArthroCare Corporation.

Advisors' Opinion:

• [By Sure Dividend]

  Health care will be necessary until we find a cure for everything. There is a less than infinitesimal chance of us finding a cure for everything in the next several decades. The following companies are Dividend Aristocrats whose revenue is generated primarily in the health care sector:

  HCP, Inc. (HCP) AbbVie (ABBV) Johnson & Johnson (JNJ) Abbott Laboratories (ABT) Walgreen (WAG) Medtronic (MDT) Becton Dickinson (BDX) Cardinal Health (CAH) C.R. Bard (BCR)

  Not to be outdone by the food and beverage industry (or perhaps due to negative health effects from the food and beverage industry), the health care industry counts nine Dividend Aristocrats in its ranks. They operate in more diverse lines of business than the food companies. HCP is a REIT that focuses on health care properties. C.R. Bard, Medtronic, and Becton Dickinson manufacture and distribute health care devices and supplies. Abbott Laboratories and Johnson & Johnson (and to a lesser extent, Cardinal Health) are well-diversified health care businesses. AbbVie was recently spun-off from Abbott Laboratories (notice the vaguely similar names), and is a pharmaceutical company.

• [By Teresa Rivas]

  Shares of Edward Lifesciences (EW) were climbing as high as 15% in Monday morning trading, after a federal court late Friday sided with the firm in its patent infringement lawsuit against Medtronic�(MDT). The decision stipulated an injunction against the sale of Medtronic�� Transcatheter valves, although the firm plans to appeal the ruling. (Medtronic, by contrast, was falling 4.2%.)

Best Warren Buffett Companies To Own For 2014: Oncothyreon Inc .(ONTY)

Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in two phase III clinical trials for the treatment of non-small cell lung cancer. The company is also developing PX-866, a small molecule that is in phase II trials for various cancer indications. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine; and ONT-701, a pan-inhibitor of the B-cell lymphoma-2 family of anti-apoptotic proteins. The company operates primarily in the United States and Canada. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Advisors' Opinion:

• [By Roberto Pedone]

  One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Oncothyreon (ONTY), which develops and markets synthetic vaccines and small molecules that treat cancer patients. This stock hasn't done much so far in 2013, with shares down modestly by 3.9%.

  If you take a look at the chart for Oncothyreon, you'll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last month and change, with shares moving between $1.63 on the downside and $1.95 on the upside. Shares of ONTY have been finding some buying interest of late right above its 50-day moving average of $1.73 a share. This stock is now starting to push within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.

  Traders should now look for long-biased trades in ONTY if it manages to break out above some near-term overhead resistance levels at $1.93 to $1.95 a share and then once it takes out more resistance at $1.98 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 689,364 shares. If that breakout triggers soon, then ONTY will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $2.12 a share to $2.70 a share.

  Traders can look to buy ONTY off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $1.73 a share or around more support at $1.63 a share. One can also buy ONTY off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Wednesday’s session are Mako Surgical Corp.(MAKO), Ascena Retail Group Inc.(ASNA) and Oncothyreon Inc.(ONTY)

• [By EP Vantage]

  Although the subgroup on which this decision is based was large, many will still consider this a risky basis for further study. Some investors thought it was a risk worth taking: shares in Oncothyreon (ONTY), which licensed the drug to Merck and saw its valuation more than halve on news of the Start failure, were trading 22% higher this morning at $2.19; Merck KGaA stock was little changed. But, in the meantime, tecemotide will struggle to shake off the stain of past failure.